[{"id":"86dcbaa4-a0f7-4722-b301-afe751349fdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT07479485","created_at":"2026-03-28T01:39:14.150Z","updated_at":"2026-03-28T01:39:14.150Z","phase":"Phase 1/2","brief_title":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","source_id_and_acronym":"NCT07479485","lead_sponsor":"Lepu Biopharma Co., Ltd.","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Puyouheng (pucotenlimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2026-03-18"},{"id":"8928481a-724a-435c-8656-726fa0e4aab3","acronym":"GLYCAR","url":"https://clinicaltrials.gov/study/NCT02905188","created_at":"2021-03-12T22:55:55.778Z","updated_at":"2025-02-25T12:26:31.981Z","phase":"Phase 1","brief_title":"Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)","source_id_and_acronym":"NCT02905188 - GLYCAR","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GLYCAR T cells • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 03/28/2019","start_date":" 03/28/2019","primary_txt":" Primary completion: 11/17/2021","primary_completion_date":" 11/17/2021","study_txt":" Completion: 01/06/2023","study_completion_date":" 01/06/2023","last_update_posted":"2025-02-24"},{"id":"6d7c8fa9-67d2-4bc9-bef1-9bdadb373194","acronym":"","url":"https://clinicaltrials.gov/study/NCT04863430","created_at":"2021-04-28T12:52:46.950Z","updated_at":"2025-02-25T13:49:08.094Z","phase":"Phase 2","brief_title":"Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach","source_id_and_acronym":"NCT04863430","lead_sponsor":"Peking University","biomarkers":" HER-2 • GPC3 • SALL4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2 • GPC3 • SALL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/11/2021","start_date":" 05/11/2021","primary_txt":" Primary completion: 07/06/2023","primary_completion_date":" 07/06/2023","study_txt":" Completion: 07/06/2023","study_completion_date":" 07/06/2023","last_update_posted":"2025-02-21"},{"id":"172cf19e-4d47-4409-b143-492fc8df438e","acronym":"GPC3","url":"https://clinicaltrials.gov/study/NCT06726161","created_at":"2025-02-26T10:02:26.236Z","updated_at":"2025-02-26T10:02:26.236Z","phase":"Phase 1","brief_title":"Study of the Theranostic Pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to Identify and Treat Subjects with GPC3+ Unresectable HCC","source_id_and_acronym":"NCT06726161 - GPC3","lead_sponsor":"RayzeBio, Inc.","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2024-12-10"},{"id":"d659973c-81cd-4913-bbf3-c30346459d0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06641453","created_at":"2025-02-25T20:22:20.737Z","updated_at":"2025-02-25T20:22:20.737Z","phase":"Phase 1/2","brief_title":"CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma","source_id_and_acronym":"NCT06641453","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/15/2024","start_date":" 11/15/2024","primary_txt":" Primary completion: 11/15/2027","primary_completion_date":" 11/15/2027","study_txt":" Completion: 11/15/2028","study_completion_date":" 11/15/2028","last_update_posted":"2024-10-16"},{"id":"6e64d8bc-6c09-4f91-9b5f-8fae5114fc10","acronym":"","url":"https://clinicaltrials.gov/study/NCT05003895","created_at":"2021-08-13T13:53:05.789Z","updated_at":"2024-07-02T16:34:38.043Z","phase":"Phase 1","brief_title":"GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)","source_id_and_acronym":"NCT05003895","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-05"},{"id":"8009476b-712f-4b6f-9467-7f222bfb4fb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05450562","created_at":"2022-07-08T14:55:40.019Z","updated_at":"2024-07-02T16:35:00.176Z","phase":"Phase 1/2","brief_title":"Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05450562","lead_sponsor":"Sanofi","biomarkers":" ALK • GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["ALK • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Libtayo (cemiplimab-rwlc) • SAR444200"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 12/12/2030","primary_completion_date":" 12/12/2030","study_txt":" Completion: 12/12/2030","study_completion_date":" 12/12/2030","last_update_posted":"2024-05-30"},{"id":"fc576648-b27b-43b1-9571-31217d6f4b7e","acronym":"ATHENA","url":"https://clinicaltrials.gov/study/NCT06084884","created_at":"2023-10-16T15:12:58.306Z","updated_at":"2024-07-02T16:35:02.183Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","source_id_and_acronym":"NCT06084884 - ATHENA","lead_sponsor":"AstraZeneca","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 12/13/2027","primary_completion_date":" 12/13/2027","study_txt":" Completion: 12/13/2027","study_completion_date":" 12/13/2027","last_update_posted":"2024-05-21"},{"id":"3901100a-b19f-4bde-96e2-eb7792963be8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06383520","created_at":"2024-04-25T17:51:38.235Z","updated_at":"2024-07-02T16:35:04.180Z","phase":"Phase 1","brief_title":"Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma","source_id_and_acronym":"NCT06383520","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/30/2023","start_date":" 09/30/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-05-13"},{"id":"2ffdf6d6-d9b4-4d82-87df-b8731e5b67ba","acronym":"ARYA3","url":"https://clinicaltrials.gov/study/NCT04864054","created_at":"2021-04-28T12:52:53.604Z","updated_at":"2024-07-02T16:35:05.862Z","phase":"Phase 2","brief_title":"T-Cell Therapy (ECT204) in Adults With Advanced HCC","source_id_and_acronym":"NCT04864054 - ARYA3","lead_sponsor":"Eureka Therapeutics Inc.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Stivarga (regorafenib) • ECT204"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-06"},{"id":"a50db79e-f985-4b65-9c1b-fc575cc8904a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04715191","created_at":"2021-01-21T06:52:06.961Z","updated_at":"2024-07-02T16:35:05.923Z","phase":"Phase 1","brief_title":"Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors","source_id_and_acronym":"NCT04715191","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GLYCAR T cells • GPC3-CAR and IL15 plus IL21 • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/03/2024","start_date":" 07/03/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 07/03/2041","study_completion_date":" 07/03/2041","last_update_posted":"2024-05-06"},{"id":"88f5020d-8814-488d-b3cb-c97d3b33e81f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05155189","created_at":"2021-12-13T14:12:43.066Z","updated_at":"2024-07-02T16:35:11.399Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT05155189","lead_sponsor":"Zhejiang University","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • AZD7003"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2041","study_completion_date":" 05/01/2041","last_update_posted":"2024-04-04"},{"id":"f07104db-d6a9-438c-a618-ef3832fea178","acronym":"","url":"https://clinicaltrials.gov/study/NCT05652920","created_at":"2022-12-15T14:58:23.337Z","updated_at":"2024-07-02T16:35:11.688Z","phase":"Phase 1/2","brief_title":"Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC","source_id_and_acronym":"NCT05652920","lead_sponsor":"OriCell Therapeutics Co., Ltd.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ori-C101"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-04-03"},{"id":"6db954e8-43a6-4f85-805a-10d3f605b83c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05783570","created_at":"2023-03-24T16:04:17.343Z","updated_at":"2024-07-02T16:35:14.560Z","phase":"Phase 1","brief_title":"To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307","source_id_and_acronym":"NCT05783570","lead_sponsor":"Eutilex","biomarkers":" IFNG • IL6 • TNFA • GPC3 • IL2 • IL10 • IL18","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • GPC3 • IL2 • IL10 • IL18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EU307"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/24/2023","start_date":" 08/24/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-15"},{"id":"a2db800b-7773-424d-82b2-c62ae0087071","acronym":"","url":"https://clinicaltrials.gov/study/NCT05022927","created_at":"2021-08-26T12:53:07.004Z","updated_at":"2024-07-02T16:35:19.713Z","phase":"Phase 1","brief_title":"A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma","source_id_and_acronym":"NCT05022927","lead_sponsor":"Chugai Pharmaceutical","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • ERY974"],"overall_status":"Recruiting","enrollment":" Enrollment 179","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-12"},{"id":"159f03cc-8156-48bf-876e-731616d2716a","acronym":"DUET-1","url":"https://clinicaltrials.gov/study/NCT05120271","created_at":"2021-11-15T12:53:36.567Z","updated_at":"2024-07-02T16:35:23.821Z","phase":"Phase 1/2","brief_title":"BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors","source_id_and_acronym":"NCT05120271 - DUET-1","lead_sponsor":"Sotio Biotech Inc.","biomarkers":" EGFR • ALK • BRCA • GPC3","pipe":" | ","alterations":" EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression","tags":["EGFR • ALK • BRCA • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BOXR1030"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/18/2022","start_date":" 05/18/2022","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 12/01/2041","study_completion_date":" 12/01/2041","last_update_posted":"2024-01-11"},{"id":"9a153527-03e4-4f0e-a267-102de598735a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05410717","created_at":"2022-06-08T11:58:15.716Z","updated_at":"2024-07-02T16:35:24.094Z","phase":"Phase 1","brief_title":"CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors","source_id_and_acronym":"NCT05410717","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" AXL • MSLN • CLDN6 • GPC3","pipe":" | ","alterations":" CLDN6 expression • CLDN6 positive","tags":["AXL • MSLN • CLDN6 • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 expression • CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6-CAR-NK cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 05/31/2034","study_completion_date":" 05/31/2034","last_update_posted":"2024-01-09"},{"id":"50719c7c-1135-486c-b135-71ad28c7d4ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT04405778","created_at":"2021-01-19T19:50:10.388Z","updated_at":"2024-07-02T16:35:25.199Z","phase":"Phase 1","brief_title":"A Study of TAK-102 in Adult With Previously-Treated Solid Tumors","source_id_and_acronym":"NCT04405778","lead_sponsor":"Takeda","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NIB102"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/10/2020","start_date":" 07/10/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-12-27"},{"id":"a01a09c6-25d1-401d-bdb6-9d279e055486","acronym":"","url":"https://clinicaltrials.gov/study/NCT05070156","created_at":"2021-10-07T12:53:00.198Z","updated_at":"2024-07-02T16:35:26.134Z","phase":"Phase 1","brief_title":"B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT05070156","lead_sponsor":"Tongji University","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e B010-A"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2023-12-15"},{"id":"f006991a-381f-4af1-aee4-1aabbfd0f738","acronym":"","url":"https://clinicaltrials.gov/study/NCT06088459","created_at":"2023-10-18T16:14:28.892Z","updated_at":"2024-07-02T16:35:32.927Z","phase":"Phase 1","brief_title":"NWRD06 DNA Plasmid for HCC After Radical Resection","source_id_and_acronym":"NCT06088459","lead_sponsor":"Newish Technology (Beijing) Co., Ltd.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-18"},{"id":"ea405aae-8f96-4a21-bb68-1a9674e78004","acronym":"IMMUNOGLYPIC","url":"https://clinicaltrials.gov/study/NCT05263830","created_at":"2022-03-03T14:06:08.514Z","updated_at":"2024-07-02T16:35:37.232Z","phase":"","brief_title":"Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy","source_id_and_acronym":"NCT05263830 - IMMUNOGLYPIC","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/08/2023","start_date":" 09/08/2023","primary_txt":" Primary completion: 09/08/2025","primary_completion_date":" 09/08/2025","study_txt":" Completion: 09/08/2027","study_completion_date":" 09/08/2027","last_update_posted":"2023-09-13"},{"id":"d3d0ed50-75d5-478b-8c9c-8d7b4f699fa1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05047510","created_at":"2021-09-17T19:53:29.595Z","updated_at":"2024-07-02T16:35:38.621Z","phase":"","brief_title":"GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma","source_id_and_acronym":"NCT05047510","lead_sponsor":"Chinese Academy of Sciences","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/10/2021","start_date":" 09/10/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-08-30"},{"id":"ee94b79f-8da0-407f-bc94-ca8110bf7bd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05103631","created_at":"2021-11-02T17:57:08.812Z","updated_at":"2024-07-02T16:35:39.256Z","phase":"Phase 1","brief_title":"Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors","source_id_and_acronym":"NCT05103631","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AGAR T cells • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/17/2021","start_date":" 06/17/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 12/01/2039","study_completion_date":" 12/01/2039","last_update_posted":"2023-08-23"},{"id":"495b5eb1-f870-47b8-a171-3b0065ad59ef","acronym":"CT0180-CG1203","url":"https://clinicaltrials.gov/study/NCT04756648","created_at":"2021-02-16T12:53:54.114Z","updated_at":"2024-07-02T16:35:42.852Z","phase":"Phase 1","brief_title":"Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma","source_id_and_acronym":"NCT04756648 - CT0180-CG1203","lead_sponsor":"Zhejiang University","biomarkers":" PD-L1 • GPC3","pipe":"","alterations":" ","tags":["PD-L1 • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CT0180"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 03/10/2021","start_date":" 03/10/2021","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-07-17"}]